RPG Life Sciences Limited
on Wednesday announced its financial results for the quarter ended June 30, 2021. RPG Life Sciences, engaged in the manufacturing and marketing of pharmaceutical products, posted a jump in profits by 50% yoy to Rs13.58cr in the quarter ended June 2021 compared to Rs9.06cr in the same quarter in last fiscal. PAT grew115% qoq from Rs6.92cr in Q4FY21, maintaining the upward trajectory in EBITDA margins, which improved from 18.9% to 21.6% yoy.
Revenue from operations at Rs108.13cr in Q1FY22 registered a growth of 18% yoy from Rs91.65cr in Q1FY21 and a growth of 17% qoq from 92.76cr in Q4FY21.
The company stock was bullish post strong Q1 earnings. The company stock hit a 52-week high of Rs538.35 per piece suring early trade on Thursday.
At around 10.10 AM, RPG Life Sciences Ltd was trading at Rs518.20 per piece up by Rs34.3 or 7.09% from its previous closing of Rs483.90 per piece on the BSE.
“In Q1FY22, the overall performance of the Company continued to be strong despite the impact of the second wave of COVID-19 pandemic. Revenue and PBT grew by 18% and 50% respectively yoy. EBITDA margin retained its upward trajectory growing from 18.9% to 21.6% yoy,” Yugal Sikri, Managing Director, RPG Life Sciences Ltd., said.